Free Trial
NASDAQ:ORIC

Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Oric Pharmaceuticals logo
$10.26 +0.41 (+4.16%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$10.28 +0.03 (+0.24%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oric Pharmaceuticals Stock (NASDAQ:ORIC)

Key Stats

Today's Range
$9.83
$10.26
50-Day Range
$9.20
$11.80
52-Week Range
$3.90
$14.67
Volume
1.16 million shs
Average Volume
750,770 shs
Market Capitalization
$996.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.63
Consensus Rating
Moderate Buy

Company Overview

Oric Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

ORIC MarketRank™: 

Oric Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 53rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oric Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Oric Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Oric Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oric Pharmaceuticals is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oric Pharmaceuticals is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oric Pharmaceuticals has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oric Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.51% of the float of Oric Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oric Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oric Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.51% of the float of Oric Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Oric Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Oric Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Oric Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oric Pharmaceuticals insiders have sold 58.30% more of their company's stock than they have bought. Specifically, they have bought $262,976.00 in company stock and sold $416,289.00 in company stock.

  • Percentage Held by Insiders

    Only 6.82% of the stock of Oric Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oric Pharmaceuticals' insider trading history.
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORIC Stock News Headlines

Chase, Bank of America, Wells Fargo Preparing for BIG Change
Thanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in America could soon begin to replace every single dollar in your bank account… With a better, more technologically advanced dollar… Potentially making a lot of people rich in the process.tc pixel
See More Headlines

ORIC Stock Analysis - Frequently Asked Questions

Oric Pharmaceuticals' stock was trading at $8.07 at the beginning of 2025. Since then, ORIC stock has increased by 27.1% and is now trading at $10.26.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01.

Oric Pharmaceuticals (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

Top institutional investors of Oric Pharmaceuticals include Alkeon Capital Management LLC (4.64%), Vivo Capital LLC (3.67%), Balyasny Asset Management L.P. (1.83%) and MPM Bioimpact LLC (1.78%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You.
View institutional ownership trends
.

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORIC
CIK
1796280
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$12.00
Potential Upside/Downside
+71.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.75%
Return on Assets
-47.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.13
Quick Ratio
16.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.34 per share
Price / Book
3.07

Miscellaneous

Outstanding Shares
97,120,000
Free Float
90,499,000
Market Cap
$996.45 million
Optionable
Optionable
Beta
1.69

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ORIC) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners